The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
SOHO UK is intended to set a precedent as the start of a continuing platform that will return at regular intervals and provide a forum for UK clinicians, trainees, and researchers to engage with international colleagues, according to meeting organisers.
Prof. Kate Cwynarski, MD, PhD, joined SOHO Insider podcast host Megan Melody, MD, for a discussion previewing lymphoma sessions she will lead at the inaugural
Andrew Lane, MD, PhD, of Dana Farber Cancer Institute, reports the results from a phase 2 trial in tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy in
The upcoming Phase 2 study will utilize a Simon 2-stage design and focus on patients who have not previously received a menin inhibitor.
Patients in the TRANSCEND FL study received liso-cel after lymphodepleting chemotherapy (LDC). Bridging therapy was allowed with reconfirmation of PET-positive disease before LDC. The primary endpoint was overall response rate (ORR) per independent review committee by PET/CT using Lugano 2014 criteria
To access the SOHO Career Center click the following link.
